ADX 10061

Drug Profile

ADX 10061

Alternative Names: ADX-10061; CEE 310; CEE-03-310; NNC 010687; NNC 687

Latest Information Update: 03 Oct 2007

Price : $50

At a glance

  • Originator Novo Nordisk
  • Developer Addex Pharmaceuticals
  • Class Antipsychotics; Benzazepines; Sleep disorder therapies; Small molecules; Smoking cessation therapies
  • Mechanism of Action Dopamine D1 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Drug abuse; Schizophrenia; Sleep disorders; Smoking withdrawal

Most Recent Events

  • 03 Oct 2007 Discontinued - Phase-II for Smoking withdrawal in USA (PO)
  • 03 Aug 2007 Discontinued - Phase-II for Drug abuse in USA (PO)
  • 03 Aug 2007 Discontinued - Phase-II for Sleep disorders in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top